Search ↗

Comparison

Kisspeptin-10 vs PT-141

Kisspeptin-10 is reproductive & HPTA; PT-141 is melanocortins. They are compared here because they are frequently considered against each other, not because they act alike.

On published evidence alone, PT-141 is the better documented of the two (regulator approved). That is a statement about the state of the literature, not a recommendation.

Kisspeptin-10 PT-141
Class Reproductive & HPTA Melanocortins
Evidence Clinical trials Regulator approved
Human trials ~25 ~20
Half-life ~4 minutes ~2.7 hours
Reported range 10-100 mcg 1-2 mg
Frequency Research protocols vary widely As needed, at most once per 24 hours and 8 doses per month
Routes Subcutaneous, Intramuscular Subcutaneous, Intranasal
FDA approved No Yes
Research use only Yes No
Banned in sport No No
Studied for Reproductive axis research, Fertility research, Sexual desire research Hypoactive sexual desire disorder in premenopausal women, Erectile dysfunction research
Reported side effects Flushing, Injection-site reactions, Headache Nausea, Flushing, Injection-site reactions, Headache, Transient blood pressure increase

Kisspeptin-10

Kisspeptin-10 is the shortest active fragment of kisspeptin, the peptide encoded by KISS1 that acts at the KISS1R receptor on hypothalamic GnRH neurons. It sits one level above GnRH in the reproductive hierarchy and is the principal gatekeeper of puberty and fertility, integrating metabolic and hormonal signals. Because it stimulates endogenous pulsatile GnRH rather than replacing it, research interest centres on inducing more physiological LH release than direct GnRH dosing achieves.

PT-141

Bremelanotide is a metabolite of melanotan II in which the C-terminal amide is replaced by a hydroxyl group, shifting selectivity toward melanocortin-4 receptors and away from MC1R. It acts on hypothalamic pathways governing sexual desire and arousal, a mechanism fundamentally different from PDE5 inhibitors, which act on penile vasculature. That distinction means it can work where sildenafil does not, and also that it does not require a vascular response to be effective.

Kisspeptin-10 vs PT-141: common questions

What is the difference between Kisspeptin-10 and PT-141?

Kisspeptin-10 is reproductive & HPTA and PT-141 is melanocortins, so they act on different pathways. Kisspeptin-10: The upstream trigger for GnRH release, and the most physiologically natural way to stimulate the reproductive axis. PT-141: A melanocortin-4 selective agonist approved for hypoactive sexual desire disorder, acting centrally rather than vascularly.

Which has stronger evidence, Kisspeptin-10 or PT-141?

PT-141 has the stronger evidence base (regulator approved, about 20 human studies) compared with Kisspeptin-10 (clinical trials).

Are Kisspeptin-10 and PT-141 FDA approved?

Only PT-141 is FDA approved (Acquired, generalised hypoactive sexual desire disorder in premenopausal women (Vyleesi)). Kisspeptin-10 is not approved for any indication.

References

Regulatory and primary sources

  1. PubChem compound record (CID 25240297) ↗ · structure, identifiers, synonyms
  2. FDA: Unapproved drugs and "research use only" products ↗ · regulatory status of non-approved products
  3. CAS Registry Number 374675-21-5 ↗ · chemical identity
  4. PubChem compound record (CID 9941379) ↗ · structure, identifiers, synonyms
  5. DailyMed: FDA-approved labeling for PT-141 ↗ · indications, dosing, warnings as approved
  6. FDA Drugs@FDA database ↗ · approval history
  7. CAS Registry Number 189691-06-3 ↗ · chemical identity

Published literature

  1. Tena-Sempere M. GPR54 and kisspeptin in reproduction.Hum Reprod Update 2006.PubMed 16731583 · doi:10.1093/humupd/dml023
  2. Ulasov IV, Borovjagin AV, Timashev P, et al.. KISS1 in breast cancer progression and autophagy.Cancer Metastasis Rev 2019.PubMed 31705228 · doi:10.1007/s10555-019-09814-4
  3. Watanabe T, Sato K. Roles of the kisspeptin/GPR54 system in pathomechanisms of atherosclerosis.Nutr Metab Cardiovasc Dis 2020.PubMed 32409274 · doi:10.1016/j.numecd.2020.02.017
  4. Garcia JP, Keen KL, Seminara SB, et al.. Role of Kisspeptin and NKB in Puberty in Nonhuman Primates: Sex Differences.Semin Reprod Med 2019.PubMed 31847024 · doi:10.1055/s-0039-3400253
  5. Arai AC. The role of kisspeptin and GPR54 in the hippocampus.Peptides 2009.PubMed 18765263 · doi:10.1016/j.peptides.2008.07.023
  6. Pastor FM, Santos BR, Silva JF, et al.. Endocrine-metabolic effects of kisspeptin in mammals.Gen Comp Endocrinol 2026.PubMed 41581529 · doi:10.1016/j.ygcen.2026.114888
  7. Prabhu VV, Sakthivel KM, Guruvayoorappan C. Kisspeptins (KiSS-1): essential players in suppressing tumor metastasis.Asian Pac J Cancer Prev 2013.PubMed 24377507 · doi:10.7314/apjcp.2013.14.11.6215
  8. Makri A, Pissimissis N, Lembessis P, et al.. The kisspeptin (KiSS-1)/GPR54 system in cancer biology.Cancer Treat Rev 2008.PubMed 18583061 · doi:10.1016/j.ctrv.2008.05.007
  9. Hedlund P. PT-141 Palatin.Curr Opin Investig Drugs 2004.PubMed 15134289
  10. Dhillon S, Keam SJ. Bremelanotide: First Approval.Drugs 2019.PubMed 31429064 · doi:10.1007/s40265-019-01187-w
  11. Pettigrew JA, Novick AM. Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment.J Midwifery Womens Health 2021.PubMed 34510696 · doi:10.1111/jmwh.13283
  12. Sweeney P, Gimenez LE, Hernandez CC, et al.. Targeting the central melanocortin system for the treatment of metabolic disorders.Nat Rev Endocrinol 2023.PubMed 37365323 · doi:10.1038/s41574-023-00855-y
  13. Lee JH, Lee JE, Harsh V, et al.. Pharmacotherapy for Sexual Dysfunction in Women.Curr Psychiatry Rep 2022.PubMed 35102537 · doi:10.1007/s11920-022-01322-7
  14. Burton CS, Mishra K. Pharmacologic therapeutic options for sexual dysfunction.Curr Opin Obstet Gynecol 2022.PubMed 36036468 · doi:10.1097/GCO.0000000000000821
  15. Nappi RE, Tiranini L, Martini E, et al.. Medical Treatment of Female Sexual Dysfunction.Urol Clin North Am 2022.PubMed 35428435 · doi:10.1016/j.ucl.2022.02.001
  16. Mayer D, Lynch SE. Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder.Ann Pharmacother 2020.PubMed 31893927 · doi:10.1177/1060028019899152

Literature retrieved from PubMed on October 16, 2026, favouring human studies and reviews. Numbered markers in the text show which paper supports which statement; uncited entries are background reading.

Read this first This page compares published reference data. It is not medical advice and not a recommendation to use either compound. Several compounds documented on this site are not approved for human use.